查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611871

冯维勒布兰德疾病治疗药物市场：依疾病类型、治疗方法、给药途径分类 - 全球预测 2025-2030

Von Willebrand Disease Treatment Market by Disease Type (Acquired VWD, Type 1, Type 2), Treatment (Clot-Stabilizing, Desmopressin, Replacement Therapies), Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年血管性血友病治疗市值为6.5312亿美元，预计2024年将达到7.1876亿美元，复合年增长率为11.30%，2030年将达到13821.2亿美元，预计将达到1000万美元。

冯·维勒布兰德病 (VWD) 治疗包括旨在控制以冯·维勒布兰德因子缺乏或功能障碍为特征的出血性疾病的治疗方法，冯·维勒布兰德因子对血液凝固很重要。对有效 VWD 治疗的需求源于其在减少出血倾向和改善患者生活品质方面的作用。治疗方法包括预防性治疗和急性出血管理，并用于各种医疗环境，包括医院、诊所和居家医疗。最终用途主要包括医疗保健提供者、患者和致力于客製化治疗方法的研究机构。市场开拓洞察表明，成长受到认识和诊断率提高、生物技术进步导致治疗方法改进以及政府对制定血友病治疗策略的支持的强烈影响。然而，高昂的治疗成本和准确诊断工具的复杂性构成了限制市场扩张的挑战。另一个限制是与某些治疗方法相关的潜在副作用，这可能会影响患者的依从性。

主要市场统计
基准年[2023] 6.5312 亿美元
预测年份 [2024] 71876万美元
预测年份 [2030] 1,382.12 百万美元
复合年增长率（%） 11.30%

个人化医疗和基因疗法的开发存在新的商机，提供有针对性的和潜在的治疗选择。先进生技药品和重组药物等技术创新提供了一条透过提高治疗效果和减少副作用来满足市场需求的途径。公司应该投资与在这些创新方面处于领先地位的研究机构进行合作研究。该市场竞争激烈但前景广阔，主要企业都专注于全面的管道开拓和策略联盟来扩大市场。为了抓住这些机会，鼓励公司在其策略中优先考虑研发、监管合规和以患者为中心的方法。儘管监管障碍和市场竞争方面的挑战仍然存在，但坚持创新和跨部门合作提供了巨大的成长潜力。透过解决这些限制并与技术进步保持一致，公司可以在 VWD 治疗领域获得竞争优势。

市场动态：针对快速发展的冯维勒布兰德病药物市场揭示的关键市场洞察

供应和需求的动态交互作用正在改变冯维勒布兰德病药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 受冯维乐布兰氏症影响的人数不断增加
    • 增加患者援助计划并增加医疗支出
    • 政府努力提高创新治疗的有效性和成功率
  • 市场限制因素
    • 与冯维勒布兰氏症药物相关的高成本
  • 市场机会
    • 冯维勒布兰氏症治疗产品核可数量增加
    • 持续开发治疗冯维乐布兰氏症的新治疗方法和诊断工具
  • 市场挑战
    • 对血管性血友病治疗药物缺乏认识

波特五力：驾驭冯维乐布兰氏症药物市场的策略工具

波特的五力架构是了解冯维勒布兰德疾病治疗药物市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解血管性血友病药物市场的外部影响

外部宏观环境因素在塑造血管性血友病治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解血管性血友病治疗药物市场的竞争状况

对冯维勒布兰德疾病治疗药物市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵冯维勒布兰德疾病治疗市场供应商的绩效评估

FPNV 定位矩阵是评估冯维勒布兰德疾病治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製冯维勒布兰德疾病治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对冯维勒布兰德疾病治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 冯·维勒布兰德病患者数量增加
      • 病患援助计划的增加和医疗成本的上升
      • 政府努力提高创新治疗方法的有效性和成功率
    • 抑制因素
      • 与冯维勒布兰氏症药物相关的高成本
    • 机会
      • 冯维勒布兰氏症治疗产品核可数量增加
      • 持续开发治疗冯维乐布兰氏症的新治疗方法和诊断工具
    • 任务
      • 对血管性血友病治疗药物缺乏认识
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章冯维乐布兰德疾病治疗药物市场：依疾病类型

  • 获得性VWD
  • 类型1
  • 2型
  • 类型3

第七章 冯维乐布兰氏症药物市场（按治疗）

  • 血栓稳定
  • 去氨加压素
  • 替代疗法

第八章冯维勒布兰德疾病治疗药物市场：依给药途径

  • 注射
  • 口服

第9章：美洲血管性血友病药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区血管性血友病药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲冯维勒布兰德病药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Accredo Health Group, Inc.
  • Affinity Biologicals Incorporated
  • ARUP Laboratories
  • AstraZeneca PLC
  • Baxter Healthcare Corporation
  • Bayer AG
  • Bio Products Laboratory Ltd.
  • Biogen Inc.
  • Bristol Myers Squibb
  • CSL Limited
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals Inc
  • Genentech Inc.
  • Grifols, SA
  • Laboratory Corporation of America Holdings
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Siemens Healthcare GmbH
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-B168537791C5

The Von Willebrand Disease Treatment Market was valued at USD 653.12 million in 2023, expected to reach USD 718.76 million in 2024, and is projected to grow at a CAGR of 11.30%, to USD 1,382.12 million by 2030.

Von Willebrand Disease (VWD) treatment encompasses therapies aimed at managing bleeding disorders characterized by a deficiency or dysfunction of the von Willebrand factor, critical for blood clotting. The necessity for effective VWD treatments stems from their role in reducing bleeding tendencies and improving patients' quality of life. Applications include prophylactic treatments and acute bleeding management, employed in diverse medical settings such as hospitals, clinics, and home care. The end-use scope primarily spans across healthcare providers, patients, and research institutes working on tailored treatment regimens. Market insights reveal that growth is strongly influenced by increasing awareness and diagnosis rates, advancements in biotechnology leading to refined therapies, and governmental support in developing hemophilia care strategies. However, high treatment costs, coupled with the complexity of creating accurate diagnostic tools, are challenges that restrain market expansion. Another limitation is the potential adverse reactions related to certain therapies, impacting patient adherence.

KEY MARKET STATISTICS
Base Year [2023] USD 653.12 million
Estimated Year [2024] USD 718.76 million
Forecast Year [2030] USD 1,382.12 million
CAGR (%) 11.30%

Emerging opportunities lie in the development of personalized medicine and gene therapies, offering targeted and potentially curative options. Technological innovations, such as advanced biologics and recombinant products, present pathways to meet market demands by enhancing treatment efficacy and reducing adverse effects. Companies should invest in collaborations with research institutions to spearhead these innovations. The market's nature is competitive yet promising, with key players focusing on comprehensive pipeline development and strategic partnerships to expand their reach. To capture these opportunities, firms are advised to prioritize R&D, regulatory compliance, and patient-centric approaches in their strategies. While challenges persist in terms of regulatory hurdles and market competition, persevering through innovation and cross-sector collaborations offers substantial growth potential. By addressing these limitations and aligning with technological advancements, businesses can secure a competitive edge in the VWD treatment landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Von Willebrand Disease Treatment Market

The Von Willebrand Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the number of people suffering from Von Willebrand disease
    • Increase in patient assistance programs and growing healthcare expenditure
    • Government initiatives to increase the efficacy and success rates of innovative treatments
  • Market Restraints
    • High cost associated with Von Willebrand disease treatment
  • Market Opportunities
    • Increasing number of product approvals for Von Willebrand disease treatment
    • Ongoing development of new treatments and diagnostic tools for Von Willebrand disease treatment
  • Market Challenges
    • Lack of awareness related to Von Willebrand disease treatment

Porter's Five Forces: A Strategic Tool for Navigating the Von Willebrand Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Von Willebrand Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Von Willebrand Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Von Willebrand Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Von Willebrand Disease Treatment Market

A detailed market share analysis in the Von Willebrand Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Von Willebrand Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Von Willebrand Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Von Willebrand Disease Treatment Market

A strategic analysis of the Von Willebrand Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Von Willebrand Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Accredo Health Group, Inc., Affinity Biologicals Incorporated, ARUP Laboratories, AstraZeneca PLC, Baxter Healthcare Corporation, Bayer AG, Bio Products Laboratory Ltd., Biogen Inc., Bristol Myers Squibb, CSL Limited, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc, Genentech Inc., Grifols, S.A., Laboratory Corporation of America Holdings, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., Siemens Healthcare GmbH, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Von Willebrand Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Acquired VWD, Type 1, Type 2, and Type 3.
  • Based on Treatment, market is studied across Clot-Stabilizing, Desmopressin, and Replacement Therapies.
  • Based on Route of Administration, market is studied across Injection and Oral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the number of people suffering from Von Willebrand disease
      • 5.1.1.2. Increase in patient assistance programs and growing healthcare expenditure
      • 5.1.1.3. Government initiatives to increase the efficacy and success rates of innovative treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with Von Willebrand disease treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing number of product approvals for Von Willebrand disease treatment
      • 5.1.3.2. Ongoing development of new treatments and diagnostic tools for Von Willebrand disease treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness related to Von Willebrand disease treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Von Willebrand Disease Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Acquired VWD
  • 6.3. Type 1
  • 6.4. Type 2
  • 6.5. Type 3

7. Von Willebrand Disease Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Clot-Stabilizing
  • 7.3. Desmopressin
  • 7.4. Replacement Therapies

8. Von Willebrand Disease Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injection
  • 8.3. Oral

9. Americas Von Willebrand Disease Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Von Willebrand Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Von Willebrand Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accredo Health Group, Inc.
  • 2. Affinity Biologicals Incorporated
  • 3. ARUP Laboratories
  • 4. AstraZeneca PLC
  • 5. Baxter Healthcare Corporation
  • 6. Bayer AG
  • 7. Bio Products Laboratory Ltd.
  • 8. Biogen Inc.
  • 9. Bristol Myers Squibb
  • 10. CSL Limited
  • 11. F. Hoffmann-La Roche AG
  • 12. Ferring Pharmaceuticals Inc
  • 13. Genentech Inc.
  • 14. Grifols, S.A.
  • 15. Laboratory Corporation of America Holdings
  • 16. Novo Nordisk A/S
  • 17. Octapharma AG
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. Siemens Healthcare GmbH
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. VON WILLEBRAND DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. VON WILLEBRAND DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. VON WILLEBRAND DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VON WILLEBRAND DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VON WILLEBRAND DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACQUIRED VWD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLOT-STABILIZING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. VON WILLEBRAND DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. VON WILLEBRAND DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023